Key Highlights
- Andrew Kidd, MD, appointed as CEO of Tentarix Biotherapeutics, previously president and CEO at Aptinyx.
- Focus on advancing internal pipeline and executing partnered programs with Gilead and AbbVie.
- Commitment to transform precision oncology and immunology using the Tentacles™ platform.
Source: Business Wire
Notable Quotes
- “We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” – Donald Santel, Chairman at Tentarix Biotherapeutics
- “I firmly believe in the company’s mission to revolutionize patient care through multi-specific biologic treatments,” – Andrew Kidd, MD, CEO at Tentarix Biotherapeutics
SoHC's Take
Andrew Kidd’s appointment as CEO of Tentarix Biotherapeutics marks a strategic move at a pivotal time for the company. With a robust background in biotech leadership, Kidd is well-positioned to steer Tentarix towards its ambitious goals. His experience at leading companies like Aptinyx and Baxter International, coupled with his fresh vision for Tentarix, suggests a promising future for the company in advancing multi-specific biologic treatments. The focus on leveraging the unique Tentacles™ platform can potentially set new benchmarks in precision medicine, particularly in oncology and immunology.
